Popular topics to explore
Mankind Pharma Slips Below Key Trend Averages
MANKIND remains a strong domestic formulations story with meaningful exposure to prescription medicines, consumer healthcare and a broad distribution network across India. The larger pharma theme continues to benefit from chronic therapy…
Pre Market Report & Global Cues| 08 September
Global cues are mixed this morning. US markets were closed due to Labour Day, so there is no fresh direction from the US side. At the same time, US 10Y yield is around 4.79%, still on the higher side. Crude is the main concern. Brent is n…
2nd Sep · SEBI Registration INH000020466
SEBI Registration INH000020466 · 2nd Sep
Mankind Pharma Exits Non-Core Hospitality Business
Mankind Pharma Limited has completed the 100% divestment of its stake in Broadway Hospitality Services Private Limited to AKRK Projects LLP for a cash consideration of ₹49 crore, effective August 31, 2026. Key Highlights: Minimal Financial…
1st Sep · SEBI Registration INH000015376
SEBI Registration INH000015376 · 1st Sep
Mankind Pharma sells 100% stake in Broadway Hospitality
Mankind Pharma has sold its 100% stake held in Broadway Hospitality Services (Broadway) to AKRK Projects LLP and its Partners. Post this transaction, Broadway has ceased to be a wholly owned subsidiary of the company with effect from August…
Mankind Pharma Ltd Mixed Technical Signals
MANKIND recent technical parameter changes highlight a nuanced shift in market assessment. Mixed signals from MACD, RSI, Bollinger Bands, and moving averages suggest a period of transition, with short-term price momentum showing mild posit…
MANKIND **Mankind Pharma Restructures BSVL Business**
** MANKIND :** The company has approved the **voluntary liquidation of Bharat Serums and Vaccines Ltd (BSVL)** as part of a restructuring exercise. Under the proposed arrangement, the BSVL business will be transferred to **Mankind Pharma**…
Mankind Pharma: Exclusive Insulin Deal Expands
Mankind Pharma Ltd ( MANKIND ) is in focus after entering into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co. Ltd. to commercialise two insulin products in India.
The products covered under t…
Mankind Pharma – Exclusive Insulin In-Licensing Deal
1. MANKIND has entered into an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical for the commercialisation of Insulin Degludec and Insulin Degludec + Aspart combination in India. The deal wi…
EMSLIMITED
**Order Wins & Pharma Licensing**
** EMSLIMITED :** Secured a **₹222 crore** order, strengthening its order book and execution pipeline.
**Impact:** **Positive;** improves revenue visibility and supports near-term growth.
** !RVNL:** S…
🚨 Mankind Pharma strengthens its diabetes portfolio! 💉📈
Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical for: 🔹 Insulin Degludec 🔹 Insulin Degludec + Aspart Combination 🎯 Why does it matter? The partnershi…
Mankind Pharma Acquisition of Bharat Serums: What It Means for Investors
MANKIND is in focus after reporting its first full quarter following the acquisition of Bharat Serums and Vaccines (BSV). The results have drawn market attention as investors assess how the acquisition is influencing the company's financia…
Update for investors of Mankind Pharma
MANKIND is currently trading at Rs. 2444.35, up by 26.35 points or 1.09% from its previous closing of Rs. 2418.00 on the BSE.
The scrip opened at Rs. 2417.95 and has touched a high and low of Rs. 2457.00 and Rs. 2415.05 respectively. So…
13th Aug · SEBI Registration INH000020466
SEBI Registration INH000020466 · 13th Aug
Mankind Pharma Incorporates Wholly-Owned Subsidiary in the Netherlands
Mankind Pharma Limited has successfully incorporated a new wholly-owned subsidiary in the Netherlands, named Mankind Pharma (Netherlands) B.V., effective August 13, 2026. This move follows the company's preliminary intimation on July 11, 20…
India Pharma Market Grows 12.1% in July, Led by Zydus Lifesciences and Sun Pharma
SUNPHARMA India’s pharmaceutical market grew 12.1% year-on-year in July 2026, marking a strong recovery after subdued growth. According to Analyst latest note, the market has maintained double-digit growth, supported by price increases, n…
About Mankind PharmaCore Focus: Known for developing, manufacturing, and marketing pharmaceutical
MANKIND About Mankind PharmaCore Focus: Known for developing, manufacturing, and marketing pharmaceutical formulations across acute and chronic therapeutic ***** Leader: Ranked #1 in prescription volume in India for over eight years, driv…
Sensex, Bankex analysis for 03/08/2026
Sensex : 78,094 > Hold long (above 77,400) > Conditional: Create short only (below 77,400) Bankex : 64,933 > Hold short (below 65,200) > Conditional: Create long only (above 65,200) F&O top gainer was : !BAJF…
Nifty midcap, Nifty JR analysis for 03/08/2026
Nifty mid select: 14,784 > Exit short. Create long (above 14,600) > Conditional: Create short only (below 14,600) Nifty JR : 73,651 > Hold long (above 72,600) > Conditional: Create short only (below 72,6…
Nifty, Banknifty, Finnifty analysis for 03/08/2026
Nifty: 24,383 > Hold long (above 23,900) > Conditional: Create short only (below 23,900) Bank Nifty: 57,264 > Hold short (below 57,500) > Conditional: Create long only (above 57,500) Fin Nifty: 26,594…
TATAPOWER
**Capex, Acquisition & Corporate Update**
** TATAPOWER :** Completed the acquisition of **100% stake in Ryapte Power Transmission**. Its subsidiary, Tata Power Renewables, also secured an **800 MW ISTS connectivity project** involving an…
MANKIND Growth Story Continues
MANKIND Mankind Pharma has witnessed a strong breakout backed by surging volumes, indicating fresh buying interest. The weekly RSI at 66.45 reflects strengthening bullish momentum without entering the overbought zone. The stock remains wel…
